

Kyle R Crassini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4208138/publications.pdf>

Version: 2024-02-01

24
papers

274
citations

1170033

9
h-index

1051228

16
g-index

25
all docs

25
docs citations

25
times ranked

506
citing authors

#	ARTICLE	IF	CITATIONS
1	The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. <i>EJHaem</i> , 2021, 2, 81-93.	1.4	4
2	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. <i>Blood Advances</i> , 2020, 4, 5093-5106.	2.5	4
3	Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. , 2020, 3, 532-549.		0
4	Molecular pathogenesis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 668-684.	1.2	12
5	Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2019, 60, 1632-1643.	0.6	7
6	Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment. <i>Blood</i> , 2019, 134, 5443-5443.	0.6	4
7	TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status. <i>Blood</i> , 2019, 134, 1735-1735.	0.6	0
8	Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 97-101.	1.2	36
9	MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 360-372.	1.2	23
10	The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 654-669.	1.2	12
11	Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 2917-2928.	0.6	13
12	Immune failure, infection and survival in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e329-e329.	1.7	18
13	The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2018, 132, 1870-1870.	0.6	0
14	ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2018, 132, 3145-3145.	0.6	0
15	mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node. <i>Blood</i> , 2018, 132, 1850-1850.	0.6	0
16	Modeling the chronic lymphocytic leukemia microenvironment in vitro. <i>Leukemia and Lymphoma</i> , 2017, 58, 266-279.	0.6	18
17	The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. <i>Leukemia and Lymphoma</i> , 2015, 56, 3407-3417.	0.6	15
18	Targeting chronic lymphocytic leukemia cells in the tumor microenvironment: A review of the in vitro and clinical trials to date. <i>World Journal of Clinical Cases</i> , 2015, 3, 694.	0.3	8

#	ARTICLE	IF	CITATIONS
19	The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2014, 124, 3326-3326.	0.6	2
20	MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling. <i>Blood</i> , 2014, 124, 3330-3330.	0.6	3
21	Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 4693-4693.	0.6	0
22	The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 729-729.	1.5	6
23	Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 99-104.	0.6	89
24	Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein. <i>Blood</i> , 2012, 120, 1804-1804.	0.6	0